ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Further Dilution of Shares

<< Previous

Bullboard Posts

Next >>

Comment by goldtechon Aug 08, 2021 3:59pm

104 Views

Post# 33669829

RE:RE:RE:Further Dilution of Shares

There you have it folks 4 cent David has told you where things are heading. He forgot to mention Biogens market cap went up by 40 Billion in one hour after phase one and what will happen to our Serology test when the CDC stops the PCR endorsement by year end, or our blood test for AD . Or . Or . Or. He is such a Bser and of course he will not admit it but he sold all his shares because next Friday he will buy back at under 20 cents. Lol he is so transparent.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments